Roivant Sciences Ltd.

NasdaqGS ROIV

Roivant Sciences Ltd. Market Capitalization on January 14, 2025: USD 7.96 B

Roivant Sciences Ltd. Market Capitalization is USD 7.96 B on January 14, 2025, a -7.72% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Roivant Sciences Ltd. 52-week high Market Capitalization is USD 9.38 B on February 27, 2024, which is 17.74% above the current Market Capitalization.
Roivant Sciences Ltd. 52-week low Market Capitalization is USD 7.41 B on August 07, 2024, which is -6.99% below the current Market Capitalization.
Roivant Sciences Ltd. average Market Capitalization for the last 52 weeks is USD 8.34 B.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqGS: ROIV

Roivant Sciences Ltd.

CEO	Mr. Matthew Gline
IPO Date	Dec. 8, 2020
Location	United Kingdom
Headquarters	11-12 St. James's Square
Employees	908
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Key trends

Past 5 years